Chao Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chao Yang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Yuanchang Hu
Hepatobiliary Center The First Affiliated Hospital with Nanjing Medical University Nanjing China
2 shared publicationsAiming Liu
Department of Critical Care Medicine, Affiliated Haian People’s Hospital of Nantong University, Nantong, China
1 shared publication- Canhui Zheng
School of Pharmacy, Naval Medical University (Second Military Medical University), Shanghai, 200433, China
1 shared publication - Chongqing Wang
School of Chemical Engineering, Zhengzhou University, Zhengzhou 450001, China
1 shared publication Chuanwei Jiang
Hepatobiliary Center The First Affiliated Hospital with Nanjing Medical University Nanjing China
1 shared publicationFei Ge
Department of Gastroenterology, Haian Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nantong, China
1 shared publication
Latest Publications
- Open Access
- 8 August 2025
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 13 (8) , e70243
Liver X Receptor Activation Alleviates Hepatic Ischemia‐Reperfusion Injury in Diabetes by Inhibiting NF‐κB–NLRP3 Activation
Introduction: Hyperglycemia has been reported to be a crucial factor that aggravates liver ischemia‐reperfusion injury (IRI). Macrophage–mediated inflammatory injury is vital to liver IRI. A positive effect of Liver X receptor (LXR) on diabetes has been proven; however, the function and mechanism of LXR in diabetic liver IRI remain unclear. Accordingly, our study concentrates on the mechanism underly. Materials and Methods: Streptozotocin (STZ, 40 mg/kg)‐treated diabetic mice were used to establish a liver IRI model. Bone marrow–derived macrophages (BMDMs) were used in studying the role of macrophage inflammation in diabetic liver. GW3965 hydrochloride was used to activate LXR in vivo and in vitro. QD394, a lipid peroxidation agonist, was used to verify the underlying mechanism. Results: Hyperglycemia exacerbates liver ischemia‐reperfusion injury (IRI) by promoting hepatic cell death and inflammation in vivo. In diabetic livers, the expression of liver X receptors (LXRs) is significantly reduced. Furthermore, the ischemia‐reperfusion process itself further decreases LXR levels. Application of the LXR agonist GW3965 mitigates macrophage lipid peroxidation and inflammasome NLRP3 (NOD‐like receptor thermal protein domain associated protein 3) inflammasome activation in vitro, thereby protecting the liver from severe IRI. The results were further confirmed by the rescue experiments. Conclusions: LXRs play an important role in diabetic liver IRI and macrophage‐associated inflammation. Pharmacologic activation of LXRs alleviates macrophage inflammatory activation in diabetic liver IRI, and may serve as a potential therapeutic target for diabetes‐related liver injury.
- 8 August 2025
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 13 (8) , e70243
Open AccessLiver X Receptor Activation Alleviates Hepatic Ischemia‐Reperfusion Injury in Diabetes by Inhibiting NF‐κB–NLRP3 Activation
Introduction: Hyperglycemia has been reported to be a crucial factor that aggravates liver ischemia‐reperfusion injury (IRI). Macrophage–mediated inflammatory injury is vital to liver IRI. A positive effect of Liver X receptor (LXR) on diabetes has been proven; however, the function and mechanism of LXR in diabetic liver IRI remain unclear. Accordingly, our study concentrates on the mechanism underly. Materials and Methods: Streptozotocin (STZ, 40 mg/kg)‐treated diabetic mice were used to establish a liver IRI model. Bone marrow–derived macrophages (BMDMs) were used in studying the role of macrophage inflammation in diabetic liver. GW3965 hydrochloride was used to activate LXR in vivo and in vitro. QD394, a lipid peroxidation agonist, was used to verify the underlying mechanism. Results: Hyperglycemia exacerbates liver ischemia‐reperfusion injury (IRI) by promoting hepatic cell death and inflammation in vivo. In diabetic livers, the expression of liver X receptors (LXRs) is significantly reduced. Furthermore, the ischemia‐reperfusion process itself further decreases LXR levels. Application of the LXR agonist GW3965 mitigates macrophage lipid peroxidation and inflammasome NLRP3 (NOD‐like receptor thermal protein domain associated protein 3) inflammasome activation in vitro, thereby protecting the liver from severe IRI. The results were further confirmed by the rescue experiments. Conclusions: LXRs play an important role in diabetic liver IRI and macrophage‐associated inflammation. Pharmacologic activation of LXRs alleviates macrophage inflammatory activation in diabetic liver IRI, and may serve as a potential therapeutic target for diabetes‐related liver injury.
- Open Access
- 17 April 2024
- Published by Springer Nature in Cytotechnology
- Vol. 76 (4) , 441-452
Pyrroloquinoline quinone protects against murine hepatitis virus strain 3-induced fulminant hepatitis by inhibiting the Keap1/Nrf2 signaling
Fulminant hepatitis (FH) is a life-threatening clinical liver syndrome characterized by substantial hepatocyte necrosis and severe liver damage. FH is typically associated with severe oxidative stress, inflammation, and mitochondrial dysfunction. Pyrroloquinoline quinone (PQQ), a naturally occurring redox cofactor, functions as an essential nutrient and antioxidant and reportedly inhibits oxidative stress and exerts potent anti-inflammatory effects. In the present study, we aimed to evaluate the therapeutic efficacy of PQQ in murine hepatitis virus strain 3 (MHV-3)-induced FH and examined the underlying mechanism. An MHV-3-induced FH mouse model was established for in vivo examination. Liver sinusoidal endothelial cells (LSECs) were used for in vitro experiments. Herein, we observed that PQQ supplementation significantly attenuated MHV-3-induced hepatic injury by suppressing inflammatory responses and reducing oxidative stress. Mechanistically, PQQ supplementation ameliorated MHV-3-induced hepatic damage by down-regulating the Keap1/Nrf2 signaling pathway in vivo and in vitro. Furthermore, Nrf2 small interfering RNA targeting LSECs abrogated the PQQ-mediated protective effects against MHV-3-related liver injury. Our results deepen our understanding of the hepatoprotective function of PQQ against MHV-3-induced liver injury and provide evidence that alleviating oxidative stress might afford a novel therapeutic strategy for treating FH.
- 17 April 2024
- Published by Springer Nature in Cytotechnology
- Vol. 76 (4) , 441-452
Open AccessPyrroloquinoline quinone protects against murine hepatitis virus strain 3-induced fulminant hepatitis by inhibiting the Keap1/Nrf2 signaling
Fulminant hepatitis (FH) is a life-threatening clinical liver syndrome characterized by substantial hepatocyte necrosis and severe liver damage. FH is typically associated with severe oxidative stress, inflammation, and mitochondrial dysfunction. Pyrroloquinoline quinone (PQQ), a naturally occurring redox cofactor, functions as an essential nutrient and antioxidant and reportedly inhibits oxidative stress and exerts potent anti-inflammatory effects. In the present study, we aimed to evaluate the therapeutic efficacy of PQQ in murine hepatitis virus strain 3 (MHV-3)-induced FH and examined the underlying mechanism. An MHV-3-induced FH mouse model was established for in vivo examination. Liver sinusoidal endothelial cells (LSECs) were used for in vitro experiments. Herein, we observed that PQQ supplementation significantly attenuated MHV-3-induced hepatic injury by suppressing inflammatory responses and reducing oxidative stress. Mechanistically, PQQ supplementation ameliorated MHV-3-induced hepatic damage by down-regulating the Keap1/Nrf2 signaling pathway in vivo and in vitro. Furthermore, Nrf2 small interfering RNA targeting LSECs abrogated the PQQ-mediated protective effects against MHV-3-related liver injury. Our results deepen our understanding of the hepatoprotective function of PQQ against MHV-3-induced liver injury and provide evidence that alleviating oxidative stress might afford a novel therapeutic strategy for treating FH.
- Open Access
- 14 March 2022
- Published by Springer Nature in Cell Death Discovery
- Vol. 8 (1) , 1-13
Hyperglycemia-triggered ATF6-CHOP pathway aggravates acute inflammatory liver injury by β-catenin signaling
Although hyperglycemia has been documented as an unfavorable element that can further induce liver ischemia–reperfusion injury (IRI), the related molecular mechanisms remain to be clearly elaborated. This study investigated the effective manner of endoplasmic reticulum (ER) stress signaling in hyperglycemia-exacerbated liver IRI. Here we demonstrated that in the liver tissues and Kupffer cells (KCs) of DM patients and STZ-induced hyperglycemic mice, the ER stress-ATF6-CHOP signaling pathway is activated. TLR4-mediated pro-inflammatory activation was greatly attenuated by the addition of 4-phenylbutyrate (PBA), one common ER stress inhibitor. The liver IRI in hyperglycemic mice was also significantly reduced after PBA treatment. In addition, deficiency of CHOP (CHOP−/−) obviously alleviates the hepatic IRI, and pro-inflammatory effects deteriorated by hyperglycemia. In hyperglycemic mice, β-catenin expression was suppressed while the ATF6-CHOP signal was activated. In the liver tissues of PBA-treated or CHOP−/− hyperglycemic mice, the expression of β-catenin was restored. Furthermore, CHOP deficiency can induce protection against hyperglycemia-related liver IRI, which was disrupted by the knockdown of β-catenin will cause this protection to disappear. High glucose (HG) treatment stimulated ATF6-CHOP signaling, reduced cellular β-catenin accumulation, and promoted the TLR4-related inflammation of BMDMs. But the above effects were partially rescued in BMDMs with CHOP deficiency or by PBA treatment. In BMDMs cultured in HG conditions, the anti-inflammatory functions of CHOP−/− were destroyed by the knockdown of β-catenin. Finally, chimeric mice carrying WT or CHOP−/− BMDMs by bone marrow transplantation were adopted to verify the above conclusion. The current study suggested that hyperglycemia could trigger ER stress-ATF6-CHOP axis, inhibit β-catenin activation, accelerate inflammation, and deteriorate liver IRI, thus providing the treatment potential for management of sterile liver inflammation in DM patients.
- 14 March 2022
- Published by Springer Nature in Cell Death Discovery
- Vol. 8 (1) , 1-13
Open AccessHyperglycemia-triggered ATF6-CHOP pathway aggravates acute inflammatory liver injury by β-catenin signaling
Although hyperglycemia has been documented as an unfavorable element that can further induce liver ischemia–reperfusion injury (IRI), the related molecular mechanisms remain to be clearly elaborated. This study investigated the effective manner of endoplasmic reticulum (ER) stress signaling in hyperglycemia-exacerbated liver IRI. Here we demonstrated that in the liver tissues and Kupffer cells (KCs) of DM patients and STZ-induced hyperglycemic mice, the ER stress-ATF6-CHOP signaling pathway is activated. TLR4-mediated pro-inflammatory activation was greatly attenuated by the addition of 4-phenylbutyrate (PBA), one common ER stress inhibitor. The liver IRI in hyperglycemic mice was also significantly reduced after PBA treatment. In addition, deficiency of CHOP (CHOP−/−) obviously alleviates the hepatic IRI, and pro-inflammatory effects deteriorated by hyperglycemia. In hyperglycemic mice, β-catenin expression was suppressed while the ATF6-CHOP signal was activated. In the liver tissues of PBA-treated or CHOP−/− hyperglycemic mice, the expression of β-catenin was restored. Furthermore, CHOP deficiency can induce protection against hyperglycemia-related liver IRI, which was disrupted by the knockdown of β-catenin will cause this protection to disappear. High glucose (HG) treatment stimulated ATF6-CHOP signaling, reduced cellular β-catenin accumulation, and promoted the TLR4-related inflammation of BMDMs. But the above effects were partially rescued in BMDMs with CHOP deficiency or by PBA treatment. In BMDMs cultured in HG conditions, the anti-inflammatory functions of CHOP−/− were destroyed by the knockdown of β-catenin. Finally, chimeric mice carrying WT or CHOP−/− BMDMs by bone marrow transplantation were adopted to verify the above conclusion. The current study suggested that hyperglycemia could trigger ER stress-ATF6-CHOP axis, inhibit β-catenin activation, accelerate inflammation, and deteriorate liver IRI, thus providing the treatment potential for management of sterile liver inflammation in DM patients.
- 1 November 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (21) , 5207-5211
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites
- 1 November 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (21) , 5207-5211
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites